Ninety beta-hemolytic Escherichia coli isolates associated with diarrhea in neonatal pigs from multiple farms in Oklahoma were investigated for known associated disease serotypes, virulence factors, ribotypes, and antimicrobial susceptibility phenotypes. Fifteen different serotypes were observed, with 58% of isolates belonging to groups that produce one of three major enterotoxins: O149, O147, and O139. Thirty percent of the swine E. coli isolates possessed a combination of F4 fimbriae and the heat-labile toxin and heat-stable toxin B enterotoxins. Seventy-three percent of the E. coli isolates were resistant to five or more antibiotics. Interestingly, 53% of swine E. coli isolates exhibited resistance to chloramphenicol (CHL), an antibiotic whose use in food animals has been prohibited in the United States since the mid-1980s. The cmlA gene, which encodes a putative CHL efflux pump, was detected by PCR in 47 of the 48 CHL-resistant isolates, and 4 of these also possessed the cat2 gene, which encodes a chloramphenicol acetyltransferase. The one CHL-resistant isolate that did not contain either cmlA or cat-2 possessed the flo gene, which confers resistance to both florfenicol and CHL. To determine whether CHL-resistant swine E. coli isolates represented dissemination of a clonal strain, all 90 isolates were analyzed by ribotyping. Seventeen distinct E. coli ribogroups were identified, with CHL resistance observed among the isolates in all except one of the major ribogroups. The identification of the cmlA gene among diverse hemolytic enterotoxigenic E. coli strains demonstrates its broad dissemination in the swine production environment and its persistence even in the absence of CHL selection pressure.
Antimicrobials are valuable tools that animal producers use to quickly address clinical disease and to maintain healthy and productive animals, but the treatment of whole herds and flocks with antimicrobials for disease prevention and growth promotion is a controversial practice (13, 16, 20, 23, 28) . Broad use of antimicrobials in agriculture selects for resistant bacteria that may enter the food chain and potentially result in foodborne illness in humans that is less responsive to treatment with conventional antibiotics. In addition to the human health concerns, antimicrobial-resistant pathogens also pose a severe and costly animal health problem, as they prolong illness and decrease productivity through higher morbidity and mortality rates.
Escherichia coli is the most common etiologic agent of neonatal diarrhea in pigs aged 0 to 4 days (7, 13) . Causative strains are usually enterotoxigenic E. coli (ETEC) isolates that colonize the small intestine and that produce one or more enterotoxins. Clinical signs of ETEC infection may first be observed within hours after birth, resulting in increased rates of mortality during the first few days of life. Treatment typically consists of a broad-spectrum antimicrobial, although resistance to such drugs has greatly increased over the last several years (1, 4, 11, 17, 22, 25) .
Chloramphenicol (CHL) is a broad-spectrum antibiotic that was used extensively in veterinary medicine until concerns over its toxicity emerged (26) . Human exposure to CHL has been linked to aplastic anemia, a type of bone marrow suppression that is usually irreversible and often fatal. Interestingly, development of the disease does not appear to be dependent on the dose or duration of exposure to CHL. The possibility that trace residues of CHL in food products may induce the disease led the U.S. Food and Drug Administration to ban its use in food animals in the 1980s (14) . Currently, only a fluorinated derivative of CHL, florfenicol (FFN), is approved for veterinary use in food animals, but FFN is not approved for use in swine in the United States.
Resistance to CHL may be mediated either enzymatically through the chemical inactivation of the drug or nonenzymatically through drug efflux. Chloramphenicol acetyltransferase catalyzes the acetylation of the 3Ј-OH of CHL and is responsible for most enzymatic resistance to CHL (27, 29) . The cmlA gene confers nonenzymatic resistance to CHL. Although its mechanism has yet to be characterized, the similarity of the primary structure of the cmlA protein to those of bacterial transport proteins suggests that it functions as a drug efflux pump (6, 32) . The flo gene, whose product shares 57% amino acid sequence identity to the product of cmlA, also encodes a putative efflux pump that confers resistance to both CHL and FFN (8, 9, 12, 21) . Additionally, Cloeckaert et al. (10) recently reported on a new flo gene variant that was identified on the R55 IncC plasmid isolated from Klebsiella pneumoniae and that also confers nonenzymatic CHL resistance.
The present study examined the antimicrobial susceptibility patterns and genetic relatedness of beta-hemolytic E. coli strains isolated from neonatal swine with diarrhea. We hypoth-esized that a high percentage of isolates would be clonal in nature and resistant to antimicrobials commonly used in swine production. Although we do report a high rate of multipledrug-resistant phenotypes, a surprisingly high incidence of resistance to CHL and FFN was observed, despite the lack of an obvious selection pressure in swine production. We further investigated the mechanisms of CHL resistance since there is limited information regarding the molecular mechanisms of resistance to this drug among hemolytic swine ETEC isolates.
RESULTS AND DISCUSSION
Antimicrobial susceptibility patterns of swine E. coli isolates. Beta-hemolytic E. coli is the most common bacterial etiologic agent of diarrhea in neonatal and postweaning pigs. Treatment of enteric E. coli infection in swine commonly includes the use of broad-spectrum antibiotics (13, 16, 23) . We characterized the patterns of susceptibility of 90 E. coli isolates from diarrheic neonatal pigs to 17 antimicrobial agents of human and veterinary therapeutic significance. The rates of resistance, as determined by measuring the MICs and comparing them to the resistance breakpoints established by NCCLS, are listed in Table 1 . The highest rates of resistance were to tetracycline (96%), sulfamethoxazole (89%), kanamycin (84%), streptomycin (82%), FFN (64%), and CHL (53%). All isolates were susceptible to nalidixic acid, ciprofloxacin, amikacin, and ceftriaxone. Resistance to multiple drugs was frequently observed, with 66 of 90 (73%) of the E. coli isolates resistant to five or more antibiotics (data not shown). The swine E. coli isolates were similar to other clinical veterinary E. coli strains in terms of their decreased susceptibilities to tetracycline, gentamicin, streptomycin, and sulfamethoxazole (1, 11, 17, 19, 22, b Resistance was based on the NCCLS breakpoint for bovine respiratory pathogens, Ն8 g/ml.
25, 30, 31). These bacterial isolates also exhibited a rate of resistance to kanamycin similar to that reported previously for bovine E. coli isolates (30), a rate of resistance to ampicillin similar to that seen for avian E. coli isolates (5), levels of susceptibility to cephalosporins similar to those seen for avian E. coli isolates (5), and levels of susceptibility to fluoroquinolones similar to those seen for bovine E. coli isolates (30) . These similarities and differences in antibiotic resistance exhibited by these three distinct veterinary groups of E. coli may reflect therapeutic use or the availability of certain antimicrobial agents for the treatment of infections in poultry, cattle, and swine as well as a shared ecology of drug resistance genes among the farm microbiota (5, 15, 20, 30) .
Tetracyclines, aminoglycosides, and sulfonamides are widely used in swine production for the treatment and prevention of disease and for growth promotion, and therefore, a high rate of resistance to drugs in these antimicrobial classes was not unexpected. The phenicols, however, are not approved for use in swine in the United States. CHL has been banned from use in food animals since the mid-1980s, and FFN is approved for use only in cattle (14) . Despite the apparent lack of selection pressure, high rates of resistance to these two antibiotics were identified in swine E. coli isolates, with 64% of isolates resistant to FFN and 53% of isolates resistant to CHL. For the CHL-resistant E. coli isolates, the CHL MIC ranged from 32 to 256 g/ml and the FFN MIC ranged from 8 to 256 g/ml (Table 2) . Most isolates (47 of 48) were resistant to CHL at 32 g/ml and FFN at 8 to 16 g/ml. For one isolate the MICs of both CHL and FFN were 256 g/ml.
The cmlA gene is widely disseminated among swine E. coli isolates. We next investigated the genetic mechanisms for resistance to CHL and FFN by assaying the swine E. coli isolates for the presence of five genes known to confer resistance to these antimicrobials: cmlA, cat-1, cat-2, cat-3, and flo. Using total genomic DNA from each of the 48 CHL-resistant isolates as the template in a PCR, we found that 47 were positive for the cmlA gene, with 4 of these isolates also possessing one of the chloramphenicol acetyltransferase genes ( Table 2) . CHL MICs were not higher for the isolates with a cmlA ϩ cat-2 ϩ genotype than for those with the cmlA gene alone, suggesting that there is no additive effect from the two resistance mechanisms.
The one CHL-resistant isolate (isolate CVM873) that did not possess either cmlA or cat-2 was positive for the flo gene and was identified as belonging to the O147 serogroup. The flo gene has been described previously and confers resistance to both FFN and CHL. The FFN and CHL MICs for this swine isolate were 256 g/ml. The high level of resistance to the phenicols in this E. coli isolate is similar to the levels of resistance exhibited by bovine E. coli isolates that possess the flo gene (30) . Although FFN is approved for use only in cattle in the United States, the presence of the flo gene has previously been reported in CHL-resistant E. coli strains isolated from chickens (19) . Only one isolate possessed the flo genotype, yet 47 of 48 isolates that were negative for flo were resistant to FFN (MICs, Ն8 g/ml). The CHL resistance gene, cmlA, does not confer resistance to FFN (12) , suggesting that a gene reservoir for FFN resistance already exists in swine E. coli isolates and involves a gene(s) other than flo and cmlA. This may present a clinical obstacle for expanded veterinary use of this drug in the treatment of E. coli-related swine enteric diseases.
CHL-resistant swine E. coli isolates do not represent expansion of a single clone. The persistence of CHL resistance in swine E. coli isolates may have resulted from continual colonization with one or a few clonal strains from a common environmental reservoir that was selected earlier when CHL was used therapeutically in the 1980s. We therefore examined the relatedness of all 90 strains according to their serotypes, ribotypes, and the presence of five virulence factors (pathotypes). The E. coli pathoypes and O serotypes are listed in Table 3 . Fifteen different serotypes were observed, with 58% of the isolates belonging to groups that produce one of three major enterotoxins, O149, O147, and O139 (7, 13). Seventynine percent (15 of 19) of O147 E. coli isolates and 72% (18 of 25) of O149 E. coli isolates were CHL resistant. Fifty-three percent (48 of 90) of swine E. coli isolates, of which 75% (36 of 48) were CHL resistant, belonged to one of two E. coli pathotypes that possessed either heat-labile toxin, heat-stable toxin B (STb), and F4 fimbriae or heat-stable toxin A, STb, Shigalike toxin 2, and F107 pili (Table 3) . Sixty-four percent (58 of 90) of the swine E. coli isolates possessed the gene for STb, and 36% (32 of 90) possessed the stx-2 gene. The most common fimbrial antigens detected were F107 (43 of 90 isolates) and F4 (33 of 90 isolates). All isolates were negative for the stx-1 or the cnf-2 gene (data not shown). These data demonstrate that CHL resistance does not exclusively belong to any one swine E. coli pathotype or O serogroup.
To determine whether CHL-resistant swine E. coli isolates represented dissemination of a clonal strain, all 90 isolates were analyzed by ribotyping. Seventeen distinct E. coli ribogroups were identified, with 83% of the isolates clustering into six major ribogroups (Fig. 1) . CHL resistance was observed among the isolates in all except one of the major ribogroups, with the largest group containing 23 of 31 isolates resistant to CHL. Seventy-nine percent of the CHL-resistant E. coli isolates were found in ribogroups 1 (n ϭ 7), 2 (n ϭ 8), and 10 (nϭ 23). The majority of ribogroups contained E. coli isolates of one serotype; however, three ribogroups (ribogroups 5, 10, and 16) contained multiple serotypes. Ribogroup 10 was the largest cluster identified (n ϭ 31) and was composed of isolates comprising primarily serotype O147 and 13 nontypeable isolates. Ribogroup 16 was the second largest cluster (n ϭ 11) and was composed of isolates of either serogroup O149 or serogroup O8, suggesting a close evolutionary relationship between these two serotypes. Ribogroups 1 and 2 contained isolates that were only of the O149 serogroup and that were genetically similar to each other; however, they vastly differed from the other ribogroup with serogroup O149 strains (ribogroup 16) (Fig. 1) . All ribogroups that possessed multiple strains (ribogroups 1, 2, 5, 7, 8, 9, 10, 11, 13, and 16) included isolates recovered from diseased swine in both 1998 and 1999 (data not shown), indicating the persistence of virulent bacterial clones. The potential for the use of ribotyping as a tool for subtyping within certain serotypes is supported by the clustering of E. coli isolates with common serotypes in different ribogroups. The different ribogroups of E. coli isolates are shown in Fig. 1 to share serotype O149 (ribogroups 1, 2, and 16), serotype O139 (ribogroups 7 and 8), and serotype O8 (ribogroups 16 and 17) . Confirmation of the appropriateness of ribotyping as a subtyping tool for pathogenic swine E. coli will require testing of additional isolates from multiple sources, time periods, and geographical locations.
Taken together with the serotyping and virulence gene data, we conclude that, unlike Salmonella enterica serovar Typhimurium DT104 (8) , the high rate of CHL resistance in our isolates does not represent the clonal expansion of a single resistant strain but the dissemination of cmlA among genetically diverse E. coli isolates. We have made similar observations with regard to the FFN resistance gene, flo, in bovine and avian E. coli isolates (19, 30) . Another possibility for the prevalence of the CHL resistance phenotype in swine E. coli isolates is that a plasmid carrying the cmlA gene is widely disseminated among these isolates. Bovine and avian E. coli isolates that are CHL resistant have been found to carry the flo gene on large plasmids that also contain genes for multiple drug resistance (19, 30) .
All 48 of our CHL-resistant isolates from swine were also resistant to at least four other drugs (data not shown). CHL resistance may be coselected with other antimicrobial resistance phenotypes if a linkage exists between their respective genes. We examined the resistance phenotypes to determine whether CHL resistance can be coselected by other antimicrobials. There was no preferential selection of CHL-resistant strains by most antimicrobials. A statistically high level of significance for coselection, however, was observed with kanamycin (P ϭ 0.0001), sulfamethoxazole (P ϭ 0.0002), and tetracycline (P ϭ 0.018), agents commonly used in swine in the United States. The use of these agents may serve to maintain plasmids on which CHL resistance determinants reside with other resistance genes. Also, cmlA may be linked to ETEC virulence plasmids (17, 18) , creating a physical linkage that would ensure the persistence of the CHL resistance phenotype among swine ETEC isolates. Further analysis of the genetic location of cmlA is needed to address this issue.
In the early 1980s, studies reported rates of CHL resistance among E. coli isolates from commercial swine herds in South Dakota and Utah of 20 and 11%, respectively (11, 22) . A survey of veterinarians at that time found that CHL was the preferred drug for the treatment of neonatal colibacillosis, a practice that presumably selected for CHL-resistant strains. The U.S. Food and Drug Administration has banned the use of CHL as a therapeutic agent in food animals since the mid1980s. Since this ban has been actively enforced, the apparent selection pressure for resistance to this drug should have been removed. Thus, our report of a 53% rate of resistance to CHL is an unexpected, but not an unprecedented, finding. Several studies in Europe have also reported persistent rates of resistance years after withdrawal of CHL as a therapeutic drug for farm animals (1, 25) . A recent report by Aarestrup et al. (2) indicated that it was possible to reduce the occurrence of antimicrobial resistance in enterococci isolated from food animals when the antimicrobial selection pressures were removed. They also demonstrated that antimicrobial resistance can persist, most likely as a consequence of coselection with other antimicrobials. The identification of the cmlA gene among diverse beta-hemolytic ETEC strains suggests the broad dissemination of this genotype in the swine production environment and suggests that CHL resistance can persist even in the absence of CHL selection pressure. This is most likely due to coselection of CHL resistance with either common swine ETEC virulence genes or other antimicrobial resistance phenotypes. Regardless, our data suggest that the withdrawal of antimicrobials from use in response to increased rates of resistance may not be an effective strategy for restoration of the therapeutic effectiveness of a specific drug. Simultaneous reductions in the selection pressures of coselecting agents may be required to reverse the emergence, spread, and persistence of antimicrobial resistance in the animal production environment.
